Tools and Resources

 

Scale for Early Psychosis Relapse Risk Assessment (SEPRRA)

Faculty:  Ashok Malla, MD, Rahul Manchanda, MD, Philip Tibbo, MD, Richard Williams, MD, Ridha Joober, MD

Sponsor: Schizophrenia Society of Canada Foundation and Otsuka-Lundbeck Alliance

In 2013, the CCEIP created an assessment tool for the prediction of relapse in early psychosis to be used in clinical settings. A multi-site study was conducted in 2016 to assess the feasibility and reliability of the tool, now named The Scale for Early Psychosis Relapse Risk Assessment (SEPRRA).

The SEPRRA tool has been assessed for feasibility and reliability, but before it can be used in routine clinical practice, the validity must be evaluated. If your clinic is interested in participating in the validation of this important tool, please reach out to Megan Connolly at megan@myelinassociates.ca for more details.

Monthly Summary of FEP and EI Publications

We are happy to share, courtesy of PEPP Montréal, a monthly summary of all newly published articles on FEP and EI. Each title is hyperlinked to the online article.  

OPTIMA: Offering Patients Therapeutic Information on Medication Alternatives

Faculty – Howard Margolese
    Sponsor - Janssen A tool for patient engagement:
    • This tool allows for a systematic discussion about the option of LAIs with patients
    • It helps to make LAIs a choice, rather than a punishment
    It is based on evidence that:
    • Relapses worsen the long term patient trajectory
    • The best way to avoid relapse is continuous antipsychotic treatment

iHope Tool

The iHope tool is available in both paper and electronic formats. It is meant to serve as a resource that can be used to support the conversation with newly diagnosed patients living with schizophrenia, reinforcing that patients can live well with this chronic illness.
    FacultyThomas Hastings, MD, FRCPC Associate Clinical Professor, Department of Psychiatry, McMaster University, Hamilton, Ontario
      Howard C. Margolese, MD, CM, MSc, FRCPC Associate Professor, Department of Psychiatry, McGill University, Montréal, Québec
        Phil Tibbo, MD, FRCPC Dr Paul Janssen Chair in Psychotic Disorders Professor, Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia

APPLY: Applying Clinical Tools - Early Psychosis Accredited Program

The APPLY: Applying Clinical Tools - Early Psychosis program was jointly developed by a national faculty, the Canadian Psychiatric Association, Janssen Inc., and Myelin & Associates. This program facilitates the opportunity for psychiatrists to apply clinical tools at point-of-care for the management of psychosis patients in the early phase of illness, and is available as either a Section 1 or Section 3 RCPSC accredited program.  

Antipsychotic Treatment Selection Tool

Project Lead: Dr. Phil Tibbo
    Project Sponsor: Janssen Inc.
        The purpose of this tool is to assist clinicians in evaluating treatment options based on individual patient factors
          • Treatment recommendations is based on the following categories:
            • Practical considerations (e.g. available formulations, po/im/dissolve, dosing frequency, cost)
            • Efficacy considerations (e.g. symptom control/response to treatment, comparison of medications)
            • Tolerability (e.g. comparison of medications based on side effects, consideration of patient medical history, use of concomitant medications)
          • Electronic format that can be used on computer and/or smart phone
           

Tool for Monitoring Antipsychotic Side Effects

Schizophrenia and use of antipsychotics are independently associated with increased motor and metabolic abnormalities, which can contribute to non-adherence to medication, and increased morbidity and mortality. The CCEIP has developed a one-page clinical assessment tool for monitoring these potential side effects along with a corresponding video.

Clinical Effectiveness

When assessing the success of a certain pharmacologic treatment for a patient with schizophrenia, there is a distinction to be made between “efficacy” and “effectiveness”. The Canadian Consortium for Early Intervention in Psychosis has created a clinical definition for ‘treatment effectiveness’ based on a sound conceptual framework, currently available evidence and clinical experience. This definition will assist clinicians in evaluating an effective response to treatment which will incorporate efficacy, tolerability and acceptance.

CCEIP Benchmark Survey

Early intervention for psychosis programs (EIPP) have been implemented in Canada without national standards of care. Other countries have developed clinical guidelines, and literature highlights several elements considered as essential. Investigations in other countries have described slow implementation of services and the frequent absence of important components. The Canadian Consortium for Early Intervention in Psychosis was formed in 2012 : one of its objectives being the development of standards of care, better knowledge of Canadian practices was needed. An on-line benchmark survey was administered in 2013 to 11 academic FEP clinics in Canada. Questions covered administrative, clinical, education and research topics.